(Q51441656)

5 April 2018

title

A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. (English)

1 reference

5 April 2018

0 references

1 reference

Hunt R

1

1 reference

5 April 2018

Fazekas B

series ordinal

2

1 reference

5 April 2018

Thorne D

series ordinal

3

1 reference

5 April 2018

Brooksbank M

series ordinal

4

1 reference

5 April 2018

publication date

1 August 1999

1 reference

5 April 2018

Journal of Pain and Symptom Management

published in

1 reference

5 April 2018

volume

18

1 reference

5 April 2018

issue

2

1 reference

5 April 2018

page(s)

111-119

1 reference

5 April 2018

Subcutaneous infusions for control of cancer symptoms

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Pharmacological Management of Cancer Pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Individual variability in the response to different opioids: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Intravenous morphine and oxycodone for pain after abdominal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Morphine and oxycodone hydrochloride in the management of cancer pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Clinical pharmacokinetics of fentanyl and its newer derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Transdermal fentanyl for pain control in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Comparative pharmacokinetics of fentanyl and alfentanil.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Withdrawal with transdermal fentanyl.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS)?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2899%2900051-2

7 January 2021

10.1016/S0885-3924(99)00051-2

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018